We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Validates USP1-PARP inhibitor combination therapy in triple-negative breast cancer, suggesting enhanced treatment efficacy.
validation for USP1-PARP inhibitor combination therapy in TNBC.
No takes yet. Share an insight, caveat, or question.
Teng et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: